Analysis of Pradaxa for Stroke Prevention (AF)-Boehringer

Boehringer announced results from a U.S. Department of Defense cohort analysis of the Military Health System database showing that non-valvular Atrial Fibrillation (NVAF) patients treated with Pradaxa (dabigatran etexilate mesylate) in routine clinical care experienced reduced rates of Stroke, major bleeding, death and other types of bleeding, along with increased lower gastrointestinal (GI) bleeding, compared to patients treated with warfarin. In this retrospective analysis, which evaluated the safety and effectiveness of Pradaxa versus warfarin in 25,586 NVAF patients, Pradaxa was associated with a 27 percent reduced risk of stroke, a primary outcome (event rate per 100 patient-years [ER] 0.92 vs. 1.32, respectively). The risk of major bleeding, the second primary outcome, was 13 percent less with Pradaxa (ER 3.08 vs. 3.70, respectively). The data were presented in a poster at the American Heart Association's Scientific Sessions.